Spil Drug Patent Portfolio

Spil owns 2 orange book drugs protected by 5 US patents Given below is the list of Spil's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10898444 Extended release multiparticulates of ranolazine 24 Jan, 2038
Active
US11510878 Extended release multiparticulates of ranolazine 24 Jan, 2038
Active
US12161761 Extended release multiparticulates of ranolazine 24 Jan, 2038
Active
US9504655 Capsule dosage form of metoprolol succinate 09 Jul, 2035
Active
US9700530 Capsule dosage form of metoprolol succinate 09 Jul, 2035
Active


Given below is the list of recent legal activities going on the following drug patents of Spil.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 13 Jan, 2025 US9700530
Patent Issue Date Used in PTA Calculation 10 Dec, 2024 US12161761
Email Notification 10 Dec, 2024 US12161761
Patent eGrant Notification 10 Dec, 2024 US12161761
Recordation of Patent eGrant 10 Dec, 2024 US12161761
Mail Patent eGrant Notification 10 Dec, 2024 US12161761
Recordation of Patent Grant Mailed 10 Dec, 2024 US12161761
Email Notification 21 Nov, 2024 US12161761
Issue Notification Mailed 20 Nov, 2024 US12161761
Dispatch to FDC 12 Nov, 2024 US12161761
Application Is Considered Ready for Issue 12 Nov, 2024 US12161761
Issue Fee Payment Verified 07 Nov, 2024 US12161761
Issue Fee Payment Received 07 Nov, 2024 US12161761
Mail Notice of Allowance 07 Aug, 2024 US12161761
Notice of Allowance Data Verification Completed 31 Jul, 2024 US12161761


Spil's Family Patents

Spil drugs have patent protection in a total of 9 countries. It's US patent count contributes only to 47.1% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Spil Drug List

Given below is the complete list of Spil's drugs and the patents protecting them.


1. Aspruzyo Sprinkle

Aspruzyo Sprinkle is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10898444 Extended release multiparticulates of ranolazine 24 Jan, 2038
(11 years from now)
Active
US11510878 Extended release multiparticulates of ranolazine 24 Jan, 2038
(11 years from now)
Active
US12161761 Extended release multiparticulates of ranolazine 24 Jan, 2038
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aspruzyo Sprinkle's drug page


2. Kapspargo Sprinkle

Kapspargo Sprinkle is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9504655 Capsule dosage form of metoprolol succinate 09 Jul, 2035
(9 years from now)
Active
US9700530 Capsule dosage form of metoprolol succinate 09 Jul, 2035
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kapspargo Sprinkle's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List